Novo Nordisk A/S (NVO) NYSE
46.19
-0.89(-1.89%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
46.19
-0.89(-1.89%)
Currency In USD
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
77406
First IPO Date
April 30, 1981
| Name | Title | Pay | Year Born |
| Maziar Mike Doustdar | President, Chief Executive Officer & Member of the Management Board | 0 | 1970 |
| Elin Jager | SVP, Chief of Staff to CEO, Corporate Strategy & Sustainability and Member of Management Board | 0 | 1986 |
| Martin Holst Lange | EVP of R&D, Chief Scientific Officer and Member of the Management Board | 1.92M | 1970 |
| Karsten Munk Knudsen | Executive Vice President, Chief Financial Officer & Member of the Management Board | 2.71M | 1971 |
| Emil Kongshøj Larsen | EVP of International Operations & Member of Management Board | 0 | 1975 |
| Jamey Millar | Executive Vice President of US Operations & Member of Management Board | 0 | 1968 |
| John F. Kuckelman | SVP, Group General Counsel, Global Legal, IP & Security and Member of Management Board | 0 | 1972 |
| Hong Chow | Executive Vice President of Product & Portfolio Strategy and Member of Management Board | 0 | 1971 |
| Tania Sabroe | EVP of People, Organisation and Corporate Affairs & Member of Management Board | 0 | 1977 |
| Thilde Hummel Bogebjerg | Executive VP of Enterprise IT & Quality and Member of Management Board | 0 | 1982 |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.